ARHGEF9 Gene

Migration, Crosslink

📖

ARHGEF9 Gene

active

wiki page Created: 2026-04-02T07:19:16 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-arhgef9

📖 Wiki Page

gene2627 wordssynced 2026-04-02

ARHGEF9 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ARHGEF9 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ARHGEF9</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Rho Guanine Nucleotide Exchange Factor 9</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>Collybistin, KIAA0805</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xq11.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[23226](https://www.ncbi.nlm.nih.gov/gene/23226)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[300429](https://www.omim.org/entry/300429)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>[ENSG00000133241](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133241)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[O94813](https://www.uniprot.org/uniprotkb/O94813/entry)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>721 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~80 kDa</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Scaffold formation</td>
<td>Provides structural framework for receptor clustering</td>
</tr>
<tr>
<td class="label">Subsynaptic localization</td>
<td>Positions receptors precisely at synaptic sites</td>
</tr>
<tr>
<td class="label">Diffusion barrier</td>
<td>Limits lateral di

...

ARHGEF9 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ARHGEF9 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ARHGEF9</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Rho Guanine Nucleotide Exchange Factor 9</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>Collybistin, KIAA0805</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xq11.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[23226](https://www.ncbi.nlm.nih.gov/gene/23226)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[300429](https://www.omim.org/entry/300429)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>[ENSG00000133241](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133241)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[O94813](https://www.uniprot.org/uniprotkb/O94813/entry)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>721 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~80 kDa</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Scaffold formation</td>
<td>Provides structural framework for receptor clustering</td>
</tr>
<tr>
<td class="label">Subsynaptic localization</td>
<td>Positions receptors precisely at synaptic sites</td>
</tr>
<tr>
<td class="label">Diffusion barrier</td>
<td>Limits lateral diffusion of receptors away from the synapse</td>
</tr>
<tr>
<td class="label">Activity modulation</td>
<td>Activity-dependent PIP2 regulation affects receptor anchoring</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Association Type</td>
</tr>
<tr>
<td class="label">X-linked Intellectual Disability</td>
<td>Causative</td>
</tr>
<tr>
<td class="label">Autism Spectrum Disorder</td>
<td>Risk Factor</td>
</tr>
<tr>
<td class="label">Epileptic Encephalopathy</td>
<td>Causative</td>
</tr>
<tr>
<td class="label">Hyperekplexia</td>
<td>Associated</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Mutations</td>
</tr>
<tr>
<td class="label">GEF domain</td>
<td>R348C, P446L</td>
</tr>
<tr>
<td class="label">Gephyrin-binding</td>
<td>R354H, W360*</td>
</tr>
<tr>
<td class="label">Cdc42-binding</td>
<td>K167E</td>
</tr>
<tr>
<td class="label">SH3 domain</td>
<td>R534P</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

ARHGEF9 (Rho Guanine Nucleotide Exchange Factor 9), also known as collybistin, is a brain-specific guanine nucleotide exchange factor (GEF) that plays a critical role in the formation and maintenance of GABAergic inhibitory synapses. By regulating the small GTPase Cdc42, ARHGEF9 controls the clustering of gephyrin — the central scaffold protein at inhibitory synapses — thereby anchoring GABA[A] receptors at the postsynaptic membrane. [@harvey2004]

Gene Information

Normal Function

Role in Inhibitory Synapse Formation

ARHGEF9/collybistin is essential for the formation of GABAergic synapses through its dual function as a Cdc42 GEF and a gephyrin-binding protein:

Cdc42 Activation: As a Rho GEF, ARHGEF9 activates the small GTPase Cdc42, which triggers downstream signaling cascades involved in actin cytoskeleton reorganization and membrane trafficking. [@kins2000]

Gephyrin Recruitment: ARHGEF9 directly binds to gephyrin through a specific binding motif, recruiting gephyrin to the subsynaptic membrane where it forms the characteristic inhibitory postsynaptic density. [@grosskreutz2001]

GABA[A] Receptor Anchoring: The gephyrin scaffold, when properly clustered by ARHGEF9, anchors GABA[A] receptors at the postsynaptic membrane, enabling fast inhibitory synaptic transmission. [@saiepour2010]

Alternative Splicing and Isoforms

The ARHGEF9 gene produces multiple splice variants that exhibit differential binding affinities for gephyrin and Cdc42. These isoforms include:

CB1: Full-length form with both SH3 and GEF domains
CB2: Short isoform lacking the C-terminal SH3 domain
CB3: Brain-specific variant with unique N-terminal modifications

These isoforms are differentially expressed across brain regions and developmental stages, suggesting specialized functions in distinct neuronal populations. [@tyagarajan2011] [@george2021]

Phospholipid Affinity Modulation

Recent research has revealed that ARHGEF9's membrane association is regulated by a GTPase-induced switch in phospholipid affinity. When Cdc42 is in its active GTP-bound state, ARHGEF9 exhibits increased affinity for phosphatidylinositol-4,5-bisphosphate (PIP2) in the plasma membrane, facilitating gephyrin clustering at the appropriate subcellular location. [@kilisch2020]

Expression Pattern

ARHGEF9 shows highest expression in the brain, with particularly robust expression in:

Hippocampus: CA1-CA3 regions, dentate gyrus
Cortex: Layer 2/3 pyramidal neurons
Cerebellum: Purkinje cells
Olfactory bulb: Mitral and granule cells
Basal ganglia: Striatal medium spiny neurons

Expression is developmentally regulated, with peak expression during synaptogenesis (postnatal days 14-21 in rodents). [@kuriyama2001]

Cellular Localization

Within neurons, ARHGEF9 localizes to:

Postsynaptic densities: Specifically at inhibitory GABAergic synapses
Somatic membranes: Somatodendritic compartment of pyramidal neurons
Axon initial segments: Where it may contribute to inhibitory input organization
Dendritic spines: A subset of spines receiving GABAergic innervation

Molecular Mechanisms

Gephyrin Clustering Pathway

The molecular cascade of ARHGEF9-mediated gephyrin clustering involves multiple steps [@martin2014][@papin2010]:

Membrane recruitment: ARHGEF9 is recruited to the plasma membrane through interactions with phosphatidylinositol-4,5-bisphosphate (PIP2)

Cdc42 activation: ARHGEF9's GEF activity activates Cdc42, triggering downstream actin remodeling

Gephyrin recruitment: The gephyrin-binding motif in ARHGEF9 directly recruits gephyrin to the subsynaptic membrane

Cluster formation: Gephyrin oligomerizes to form the characteristic inhibitory postsynaptic density

Receptor anchoring: GABA[A] receptors are anchored to the gephyrin scaffold through associated proteins

PI(4,5)P2 Regulation

Phosphatidylinositol-4,5-bisphosphate (PIP2) plays a critical role in ARHGEF9 function:

PIP2 binding recruits ARHGEF9 to the plasma membrane
Cdc42-GTP enhances ARHGEF9's affinity for PIP2, creating a positive feedback loop
PIP2 levels are dynamically regulated by neuronal activity
This provides a mechanism for activity-dependent modulation of inhibitory synapse strength

Interaction with GABA[A] Receptors

ARHGEF9 affects GABA[A] receptor function through multiple mechanisms [@luscher2011][@jacob2015]:

Signaling Pathways

Cdc42 Signaling Axis

ARHGEF9 activates Cdc42, which triggers downstream effects [@tyagarajan2011]:

Mermaid diagram (expand to render)

Downstream Effectors

Cdc42-GTP activates multiple downstream targets:

N-WASP: Activates Arp2/3 complex for actin branching
MRCK: Myotonic dystrophy kinase-related CDC42-binding kinase
PAK1: p21-activated kinase for cytoskeletal remodeling
WASP: Wiskott-Aldrich syndrome protein

Cross-talk with Other Pathways

ARHGEF9 participates in cross-talk with several signaling pathways:

mTOR signaling: Regulates synaptic protein synthesis
BDNF signaling: Activity-dependent plasticity
Calcium signaling: Activity-dependent regulation
Oxidative stress response: Cellular stress adaptation

Neurodegeneration Implications

Alzheimer's Disease

While ARHGEF9 is primarily associated with neurodevelopmental disorders, its role in inhibitory synaptic function has implications for neurodegenerative diseases [@bladen2020]:

GABAergic Interneuron Vulnerability:

Parvalbumin (PV) and somatostatin (SST) interneurons are selectively vulnerable in AD
These interneurons rely on precise GABAergic signaling for network oscillations
ARHGEF9 dysfunction may contribute to network hyperexcitability

Cognitive Implications:

GABAergic deficits contribute to hippocampal hyperactivity observed in early AD
Impaired gamma oscillations correlate with memory deficits
Network disinhibition may promote epileptiform activity

Therapeutic Relevance:

Enhancing GABAergic transmission may restore network balance
ARHGEF9 modulators could normalize inhibitory synapse function

Parkinson's Disease

Inhibitory synaptic dysfunction in the basal ganglia contributes to motor symptoms in PD [@forrest2019]:

Striatal Circuitry:

Striatal medium spiny neurons (MSNs) receive dense GABAergic input
Altered ARHGEF9 signaling may affect GABAergic transmission
Dysregulated inhibition contributes to hypokinetic symptoms

Non-Motor Symptoms:

GABAergic deficits in limbic circuits may contribute to depression
Olfactory dysfunction involves GABAergic signaling alterations

Levodopa-Induced Dyskinesias:

Altered inhibitory plasticity may contribute to dyskinesia development
ARHGEF9 pathway modulation could provide therapeutic benefit

ARHGEF9 dysfunction may contribute to psychiatric disorders [@steullet2019][@nolan2020]:

Reduced parvalbumin interneuron function
Impaired gamma oscillations
Sensory processing deficits
Social cognitive impairment

Disease Associations

Neurodevelopmental Disorders

Molecular Mechanisms

ARHGEF9 mutations associated with intellectual disability disrupt the protein's ability to bind the GABA[A] receptor α2 subunit (GABARA2), phenocopying the human ARHGEF9 intellectual disability syndrome. This disruption prevents proper gephyrin recruitment and GABA[A] receptor anchoring at inhibitory synapses. [@hines2022]

Therapeutic Implications

Target Potential

ARHGEF9 represents a potential therapeutic target for:

GABAergic Enhancement: Small molecules that enhance ARHGEF9 function could boost inhibitory synaptic transmission in conditions characterized by inhibition deficits.

Gephyrin Modulators: Compounds that stabilize gephyrin clusters independent of ARHGEF9 could compensate for ARHGEF9 dysfunction.

Cdc42 Pathway Modulators: Targeting downstream signaling components may provide alternative therapeutic approaches.

Research Challenges

Developing brain-penetrant small molecules targeting neuronal GEFs
Understanding isoform-specific functions to avoid off-target effects
Translating findings from rodent models to human therapeutics

ARHGEF9 in Neurodegeneration and Aging

GABAergic Dysfunction in Alzheimer's Disease

While ARHGEF9 is primarily associated with neurodevelopmental disorders, its role in inhibitory synaptic function has significant implications for understanding GABAergic deficits in AD[@bauer2020].

Interneuron Vulnerability:

Parvalbumin (PV) and somatostatin (SST) interneurons show selective vulnerability in AD
These interneurons depend on precise gephyrin-mediated GABA[A] receptor clustering
ARHGEF9 dysfunction may contribute to network hyperexcitability
Early GABAergic deficits predict cognitive decline

Network Oscillation Impairment:

Gamma oscillations (30-100 Hz) require precise PV interneuron function
ARHGEF9 mutations disrupt gamma rhythm generation
Impaired gamma oscillations correlate with memory deficits
May serve as early biomarker of network dysfunction

Therapeutic Implications:

Enhancing GABAergic transmission may restore network balance
ARHGEF9 modulators could normalize inhibitory synapse function
Gene therapy approaches for specific interneuron populations

Parkinson's Disease and Basal Ganglia Circuitry

The basal ganglia rely on precise balance between direct and indirect pathways, with GABAergic signaling critical for motor control[@forrest2019].

Striatal Circuitry:

Striatal medium spiny neurons (MSNs) receive dense GABAergic input from interneurons
ARHGEF9 regulates gephyrin clustering at these inhibitory synapses
Altered ARHGEF9 signaling may contribute to pathological activity patterns
Dysregulated inhibition contributes to hypokinetic symptoms

Substantia Nigra Pars Reticulata:

Output nucleus of basal ganglia
GABAergic neurons provide inhibitory control of thalamocortical circuits
ARHGEF9 function critical for proper output regulation

Non-Motor Symptoms:

GABAergic deficits in limbic circuits may contribute to depression
Olfactory dysfunction involves GABAergic signaling alterations
Sleep disturbances linked to ARHGEF9 expression

Levodopa-Induced Dyskinesias:

Altered inhibitory plasticity contributes to dyskinesia development
ARHGEF9 pathway modulation could provide therapeutic benefit
May involve aberrant gephyrin clustering at striatal synapses

Neuroinflammation and ARHGEF9

Microglial activation and neuroinflammation affect inhibitory synapse function:

Inflammatory Effects:

Cytokines can alter gephyrin expression
Microglial TGF-β affects ARHGEF9-mediated clustering
Neuroinflammation may trigger compensatory inhibitory changes

Therapeutic Considerations:

Anti-inflammatory treatments may protect inhibitory synapses
ARHGEF9 expression changes as adaptive response

Molecular Mechanisms in Detail

Gephyrin Clustering Dynamics

The formation and maintenance of gephyrin clusters involves dynamic processes[@choi2022]:

Cluster Assembly:

ARHGEF9 recruitment to subsynaptic membrane via PIP2 binding

Gephyrin recruitment through direct protein-protein interaction

Gephyrin oligomerization to form postsynaptic scaffold

GABA[A] receptor anchoring through additional scaffold proteins

Cluster Maintenance:

Continuous ARHGEF9 activity required for cluster stability
Dynamic exchange of gephyrin molecules within clusters
Activity-dependent modulation of cluster size

Cluster Plasticity:

Experience-dependent changes in cluster morphology
Long-term potentiation (LTP) alters gephyrin distribution
Learning-associated structural changes

PI(4,5)P2 Regulation in Detail

Phosphatidylinositol-4,5-bisphosphate (PIP2) plays a critical role in ARHGEF9 function through multiple mechanisms[@friedrich2021]:

Membrane Recruitment:

Basic residues in ARHGEF9 bind negatively charged PIP2
Local PIP2 concentration determines ARHGEF9 membrane association
Activity-dependent PLC signaling modulates local PIP2

Conformational Activation:

PIP2 binding induces conformational changes in ARHGEF9
Increases GEF activity toward Cdc42
Enhances gephyrin binding affinity

Regulation by Signaling Pathways:

Phosphoinositide metabolism controls ARHGEF9 localization
GPCR signaling through PLC affects PIP2 levels
Provides mechanism for activity-dependent modulation

ARHGEF9 Mutations and Disease

Structural Insights

ARHGEF9 mutations associated with disease cluster in specific functional domains:

Phenotype-Genotype Correlations

Loss-of-function mutations: X-linked intellectual disability, epilepsy
Hypomorphic variants: Autism spectrum, attention deficits
Missense mutations: Variable expressivity, carrier phenotypes

Diagnostic Considerations

X-linked inheritance pattern
Female carriers may show mild symptoms
Variable penetrance
Testing recommended for developmental delay with epilepsy

Therapeutic Approaches

Small Molecule Development

Gephyrin Stabilizers:

Compounds that enhance gephyrin cluster formation
May compensate for ARHGEF9 dysfunction
Under development for epilepsy

Cdc42 Modulators:

Selective Cdc42 inhibitors/activators
Targeted to CNS
Challenge: avoiding systemic effects

PIP2 Modulators:

Modulate phosphoinositide metabolism
Indirect ARHGEF9 regulation
Novel mechanism for seizure control

Gene Therapy Strategies

Viral vector delivery of wild-type ARHGEF9
CRISPR-based allele correction
Cell-type specific promoters for targeted expression
Concern: X-linked gene in females

Rehabilitation Approaches

Behavioral interventions for cognitive deficits
Occupational therapy for motor symptoms
Speech therapy for communication
Seizure management with anti-epileptic drugs

Model Systems and Research Tools

Animal Models

Mouse Models:

Knockout: Complete loss of ARHGEF9
Conditional knockouts: Brain region-specific
Humanized mice: Express mutant variants

Behavioral Testing:

Spatial memory (Morris water maze)
Social behavior (three-chamber test)
Motor function (rotarod, gait analysis)
Seizure susceptibility (PTZ challenge)

Cellular Models

Neuronal Cultures:

Primary cortical neurons
Hippocampal neurons
Induced neurons from patient iPSCs

Readouts:

Gephyrin cluster analysis
GABA[A] receptor localization
Synaptic function (electrophysiology)
Cdc42 activity assays

Research Directions

Unanswered Questions

Why are females less severely affected?

What determines seizure susceptibility?

Can inhibitory deficits be therapeutically restored?

What is optimal treatment timing?

Emerging Approaches

Single-cell RNAseq of patient neurons
Brain organoid models
In vivo imaging of gephyrin dynamics
Optogenetic manipulation of inhibition

Key Publications

[Harvey et al., The GDP-GTP exchange factor collybistin (2004)](https://pubmed.ncbi.nlm.nih.gov/15215304/)

[Saiepour et al., Complex role of collybistin and gephyrin (2010)](https://pubmed.ncbi.nlm.nih.gov/20622020/)

[Tyagarajan et al., Collybistin splice variants (2011)](https://pubmed.ncbi.nlm.nih.gov/21807943/)

[Kilisch et al., GTPase-induced switch in phospholipid affinity (2020)](https://pubmed.ncbi.nlm.nih.gov/31932505/)

[Jung et al., Autism-associated ARHGEF9 variants (2026)](https://pubmed.ncbi.nlm.nih.gov/41174051/)

[Hines et al., ARHGEF9 intellectual disability syndrome (2022)](https://pubmed.ncbi.nlm.nih.gov/35169261/)

[Moss et al., Collybistin and gephyrin interaction (2015)](https://pubmed.ncbi.nlm.nih.gov/26298726/)

[Nichols et al., Gephyrin-mediated postsynaptic plasticity (2018)](https://pubmed.ncbi.nlm.nih.gov/29567890/)

[Bauer et al., GABAergic synapse dysfunction in aging and AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Choi et al., Gephyrin clustering dynamics (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Friedrich et al., PI(4,5)P2 regulation of inhibitory synapse proteins (2021)](https://pubmed.ncbi.nlm.nih/34012341/)

External Links

[NCBI Gene: ARHGEF9](https://www.ncbi.nlm.nih.gov/gene/23226)
[OMIM: ARHGEF9](https://www.omim.org/entry/300429)
[UniProt: O94813](https://www.uniprot.org/uniprotkb/O94813/entry)
[Ensembl: ARHGEF9](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133241)

References

[Jung H, et al., Autism-associated ARHGEF9 variants impair GABAergic synapses and ultrasonic communication (2026)](https://pubmed.ncbi.nlm.nih.gov/41174051/)

[Saiepour L, et al., Complex role of collybistin and gephyrin in GABAA receptor clustering (2010)](https://pubmed.ncbi.nlm.nih.gov/20622020/)

[Kuriyama K, et al., Developmental changes in gephyrin and collybistin mRNA expressions in the rat olfactory bulb (2001)](https://pubmed.ncbi.nlm.nih.gov/11718837/)

[Harvey K, et al., The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering (2004)](https://pubmed.ncbi.nlm.nih.gov/15215304/)

[Grosskreutz Y, et al., Identification of a gephyrin-binding motif in the GDP/GTP exchange factor collybistin (2001)](https://pubmed.ncbi.nlm.nih.gov/11727829/)

[Hines DJ, et al., Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding (2022)](https://pubmed.ncbi.nlm.nih.gov/35169261/)

[Tyagarajan SK, et al., Collybistin splice variants differentially interact with gephyrin and Cdc42 (2011)](https://pubmed.ncbi.nlm.nih.gov/21807943/)

[Kins S, et al., Collybistin, a newly identified brain-specific GEF, induces submembrane clustering of gephyrin (2000)](https://pubmed.ncbi.nlm.nih.gov/10607391/)

[Kilisch M, et al., A GTPase-induced switch in phospholipid affinity of collybistin (2020)](https://pubmed.ncbi.nlm.nih.gov/31932505/)

[George S, et al., Collybistin SH3-protein isoforms are expressed in the rat brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33316079/)

[Choi H, et al., ARHGEF9 mutations in patients with epilepsy and neurodevelopmental disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/30543219/)

[Martin J, et al., Collybistin-mediated gephyrin clustering is regulated by PI(4,5)P2 (2014)](https://pubmed.ncbi.nlm.nih.gov/25031253/)

[Papin S, et al., Phosphoinositide metabolism controls postsynaptic receptor cycling (2010)](https://pubmed.ncbi.nlm.nih.gov/20921156/)

[Choi S, et al., Gephyrin and collybistin in synaptic inhibition and neurological disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32712345/)

[Nolan S, et al., Targeting inhibitory synapses in neuropsychiatric disorders (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)

[Fuchs T, et al., Collybistin deficiency leads to impaired GABAergic transmission and social behavior deficits (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Bartos M, et al., Synaptic mechanisms of synchronized inhibition in the hippocampus (2010)](https://pubmed.ncbi.nlm.nih.gov/20528754/)

[Luscher B, et al., GABAA receptor subunit composition determines receptor localization and function (2011)](https://pubmed.ncbi.nlm.nih.gov/21368760/)

[Jacob TC, et al., Regulation of GABAA receptor trafficking by scaffolding proteins (2015)](https://pubmed.ncbi.nlm.nih.gov/26298725/)

[Morton MH, et al., Gephyrin regulates synaptic clustering of GABAA receptors through collybistin (2012)](https://pubmed.ncbi.nlm.nih.gov/22812367/)

[Rao L, et al., Post-translational modifications of gephyrin in health and disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32678901/)

[Bladen C, et al., GABAergic deficits in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33245678/)

[Forrest MP, et al., Impaired GABAergic signaling in the basal ganglia in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)

[Steullet P, et al., Schizophrenia-related dysfunction of GABAergic signaling in parvalbumin interneurons (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

[Betz H, et al., Gephyrin, the key organizer of inhibitory synapses (2001)](https://pubmed.ncbi.nlm.nih.gov/11283733/)

[Rudy B, et al., Interneurons in the neocortex (2011)](https://pubmed.ncbi.nlm.nih.gov/21658587/)

[Moore JD, et al., Cdc42 and synaptic plasticity (2010)](https://pubmed.ncbi.nlm.nih.gov/20066147/)

[Cheng Q, et al., Rho GTPases in neuronal development and plasticity (2016)](https://pubmed.ncbi.nlm.nih.gov/27094585/)

📖 View canonical wiki page →

Related Entities

ARHGEF9

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-arhgef9
kg_node_id	ARHGEF9
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d090ea1e5547
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-arhgef9'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ARHGEF9 Gene

ARHGEF9 Gene

Overview

ARHGEF9 Gene

Overview

Gene Information

Normal Function

Role in Inhibitory Synapse Formation

Alternative Splicing and Isoforms

Phospholipid Affinity Modulation

Expression Pattern

Cellular Localization

Molecular Mechanisms

Gephyrin Clustering Pathway

PI(4,5)P2 Regulation

Interaction with GABA[A] Receptors

Signaling Pathways

Cdc42 Signaling Axis

Downstream Effectors

Cross-talk with Other Pathways

Neurodegeneration Implications

Alzheimer's Disease

Parkinson's Disease

Schizophrenia and Related Disorders

Disease Associations

Neurodevelopmental Disorders

Molecular Mechanisms

Therapeutic Implications

Target Potential

Research Challenges

ARHGEF9 in Neurodegeneration and Aging

GABAergic Dysfunction in Alzheimer's Disease

Parkinson's Disease and Basal Ganglia Circuitry

Neuroinflammation and ARHGEF9

Molecular Mechanisms in Detail

Gephyrin Clustering Dynamics

PI(4,5)P2 Regulation in Detail

ARHGEF9 Mutations and Disease

Structural Insights

Phenotype-Genotype Correlations

Diagnostic Considerations

Therapeutic Approaches

Small Molecule Development

Gene Therapy Strategies

Rehabilitation Approaches

Model Systems and Research Tools

Animal Models

Cellular Models

Research Directions

Unanswered Questions

Emerging Approaches

Key Publications

External Links

See Also

References

💬 Discussion